{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:30:32Z","timestamp":1791894632815,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Project of Tianjin Municipal Education Commission","award":["2022ZD069"],"award-info":[{"award-number":["2022ZD069"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31042-w","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T15:24:54Z","timestamp":1765380294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["E2F transcription factors as multimodal biomarkers for pan-cancer management"],"prefix":"10.1038","volume":"16","author":[{"given":"Shaobo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Suo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkai","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"31042_CR1","first-page":"1","volume":"2021","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. Pan-cancer analysis of the prognostic and immunological role of HSF1: A potential target for survival and immunotherapy. Oxid. Med. Cell. Longev. 2021, 1\u201321 (2021).","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"5","key":"31042_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/0113892029255941231014142050","volume":"24","author":"J Qiu","year":"2023","unstructured":"Qiu, J. et al. Pan-cancer analysis identifies AIMP2 as a potential biomarker for breast cancer. Curr Genomics. 24(5), 307\u2013329 (2023).","journal-title":"Curr Genomics."},{"issue":"3","key":"31042_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/0109298665351592250106062250","volume":"32","author":"G Lyu","year":"2025","unstructured":"Lyu, G. & Li, D. ZNF165: A pan-cancer biomarker with prognostic and therapeutic potential. Protein Pept Lett. 32(3), 206\u2013223 (2025).","journal-title":"Protein Pept Lett."},{"issue":"5","key":"31042_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2174\/0115665232331353240911080642","volume":"25","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Pan-cancer single-cell analysis revealing the heterogeneity of cancer-associated fibroblasts in skin tumors. Curr. Gene. Ther. 25(5), 793\u2013821 (2024).","journal-title":"Curr. Gene. Ther."},{"key":"31042_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41698-018-0075-9","volume":"3","author":"HA Loomans-Kropp","year":"2019","unstructured":"Loomans-Kropp, H. A. & Umar, A. Cancer prevention and screening: the next step in the era of precision medicine. NPJ. Precis. Oncol. 3, 3 (2019).","journal-title":"NPJ. Precis. Oncol."},{"key":"31042_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113844","volume":"176","author":"Q Xiao","year":"2021","unstructured":"Xiao, Q. et al. High-throughput proteomics and AI for cancer biomarker discovery. Adv. Drug Deliv. Rev. 176, 113844 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"31042_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1566523223666221219094849","volume":"23","author":"AK Singh","year":"2023","unstructured":"Singh, A. K. & Malviya, R. DNA vaccines to improve immunogenicity and effectiveness in cancer vaccinations: advancement and developments. Curr. Gene Ther. 23(3), 170\u2013183 (2023).","journal-title":"Curr. Gene Ther."},{"issue":"5","key":"31042_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2174\/156652322305230808102847","volume":"23","author":"S Paul","year":"2023","unstructured":"Paul, S. MicroRNA theranostics in cancer. Curr. Gene Ther. 23(5), 329 (2023).","journal-title":"Curr. Gene Ther."},{"issue":"1","key":"31042_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1566523222666220830150446","volume":"23","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. The role of rna m6a modification in cancer glycolytic reprogramming. Curr. Gene Ther. 23(1), 51\u201359 (2023).","journal-title":"Curr. Gene Ther."},{"issue":"1","key":"31042_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2174\/1566523222666220831161225","volume":"23","author":"ME Dashtaki","year":"2023","unstructured":"Dashtaki, M. E. & Ghasemi, S. CRISPR\/Cas9-based gene therapies for fighting drug resistance mediated by cancer stem cells. Curr. Gene Ther. 23(1), 41\u201350 (2023).","journal-title":"Curr. Gene Ther."},{"key":"31042_CR11","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429308361240823061634","volume":"17","author":"L Qiong","year":"2024","unstructured":"Qiong, L. et al. Recent advances in the glycolytic processes linked to tumor metastasis. Curr. Mol. Pharmacol. 17, e18761429308361 (2024).","journal-title":"Curr. Mol. Pharmacol."},{"issue":"6","key":"31042_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","volume":"19","author":"LN Kent","year":"2019","unstructured":"Kent, L. N. & Leone, G. The broken cycle: E2F dysfunction in cancer. Nat. Rev. Cancer 19(6), 326\u2013338 (2019).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"31042_CR13","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrc2696","volume":"9","author":"HZ Chen","year":"2009","unstructured":"Chen, H. Z., Tsai, S. Y. & Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9(11), 785\u2013797 (2009).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"31042_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrc2696","volume":"9","author":"HZ Chen","year":"2009","unstructured":"Chen, H. Z. et al. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9(11), 785\u2013797 (2009).","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"31042_CR15","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/cells9071643","volume":"9","author":"M Oshi","year":"2020","unstructured":"Oshi, M. et al. The E2F pathway score as a predictive biomarker of response to neoadjuvant therapy in ER+\/HER2\u2212 breast cancer. Cells 9(7), 1643 (2020).","journal-title":"Cells"},{"issue":"7","key":"31042_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158995","volume":"11","author":"S Marczok","year":"2016","unstructured":"Marczok, S. et al. Comprehensive analysis of genome rearrangements in eight human malignant tumor tissues. PLoS ONE 11(7), e0158995 (2016).","journal-title":"PLoS ONE"},{"issue":"1","key":"31042_CR17","doi-asserted-by":"publisher","first-page":"7765","DOI":"10.1080\/21655979.2021.1985340","volume":"12","author":"H Luo","year":"2021","unstructured":"Luo, H. et al. Early 2 factor (E2F) transcription factors contribute to malignant progression and have clinical prognostic value in lower-grade glioma. Bioengineered 12(1), 7765\u20137779 (2021).","journal-title":"Bioengineered"},{"issue":"1","key":"31042_CR18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3892\/ijo.2016.3791","volume":"50","author":"JP Wang","year":"2017","unstructured":"Wang, J. P. et al. Rb knockdown accelerates bladder cancer progression through E2F3 activation. Int. J. Oncol. 50(1), 149\u2013160 (2017).","journal-title":"Int. J. Oncol."},{"issue":"3","key":"31042_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2174\/1573412919666221223152915","volume":"19","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Metabolomics-based approach to analyze the therapeutic targets and metabolites of a synovitis ointment for knee osteoarthritis. Curr. Pharm. Anal. 19(3), 222\u2013234 (2023).","journal-title":"Curr. Pharm. Anal."},{"key":"31042_CR20","doi-asserted-by":"publisher","DOI":"10.2174\/1874467216666230306101653","volume":"17","author":"Z Ma","year":"2024","unstructured":"Ma, Z. et al. E2F1 reduces sorafenib\u2019s sensitivity of esophageal carcinoma cells via modulating the miR-29c-3p\/COL11A1 signaling axis. Curr. Mol. Pharmacol. 17, e060323214360 (2024).","journal-title":"Curr. Mol. Pharmacol."},{"key":"31042_CR21","doi-asserted-by":"publisher","DOI":"10.2174\/1874467216666230217151946","volume":"17","author":"Q Zeng","year":"2024","unstructured":"Zeng, Q. et al. Hsa_Circ_0000021 sponges miR-3940-3p\/KPNA2 expression to promote cervical cancer progression. Curr. Mol. Pharmacol. 17, e170223213775 (2024).","journal-title":"Curr. Mol. Pharmacol."},{"issue":"1","key":"31042_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2174\/1874467215666220308122716","volume":"16","author":"X Peng","year":"2023","unstructured":"Peng, X. et al. MiR-129-2-3p inhibits esophageal carcinoma cell proliferation, migration, and invasion via targeting DNMT3B. Curr. Mol. Pharmacol. 16(1), 116\u2013123 (2023).","journal-title":"Curr. Mol. Pharmacol."},{"issue":"23","key":"31042_CR23","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.3390\/cancers13236092","volume":"13","author":"G Yu","year":"2021","unstructured":"Yu, G. et al. Tumor mutation burden, expressed neoantigens and the immune microenvironment in diffuse gliomas. Cancers (Basel) 13(23), 6092 (2021).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"31042_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","volume":"76","author":"B Scheiner","year":"2022","unstructured":"Scheiner, B. et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J. Hepatol. 76(2), 353\u2013363 (2022).","journal-title":"J. Hepatol."},{"issue":"1","key":"31042_CR25","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1038\/s41467-021-26974-6","volume":"12","author":"D Phillips","year":"2021","unstructured":"Phillips, D. et al. Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. Nat. Commun. 12(1), 6726 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"31042_CR26","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1038\/s41467-020-17965-0","volume":"11","author":"AA Hakimi","year":"2020","unstructured":"Hakimi, A. A. et al. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nat. Commun. 11(1), 4168 (2020).","journal-title":"Nat. Commun."},{"issue":"2","key":"31042_CR27","doi-asserted-by":"publisher","first-page":"e000293","DOI":"10.1136\/jitc-2019-000293","volume":"8","author":"M Li","year":"2020","unstructured":"Li, M. et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J. Immunother Cancer 8(2), e000293 (2020).","journal-title":"J. Immunother Cancer"},{"key":"31042_CR28","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933443","volume":"27","author":"L Luo","year":"2021","unstructured":"Luo, L. et al. Prognostic value of E2F transcription factor expression in pancreatic adenocarcinoma. Med. Sci. Monit. 27, e933443 (2021).","journal-title":"Med. Sci. Monit."},{"key":"31042_CR29","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.61287","volume":"9","author":"PA Roelofs","year":"2020","unstructured":"Roelofs, P. A. et al. Characterization of the mechanism by which the RB\/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B. Elife 9, e61287 (2020).","journal-title":"Elife"},{"key":"31042_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.606735","volume":"10","author":"XS Liu","year":"2020","unstructured":"Liu, X. S. et al. Comprehensive analysis of prognostic and immune infiltrates for E2F transcription factors in human pancreatic adenocarcinoma. Front. Oncol. 10, 606735 (2020).","journal-title":"Front. Oncol."},{"issue":"3","key":"31042_CR31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/cancers11030274","volume":"11","author":"YD Jung","year":"2019","unstructured":"Jung, Y. D. et al. Lactate activates the E2F pathway to promote cell motility by up-regulating microtubule modulating genes. Cancers (Basel) 11(3), 274 (2019).","journal-title":"Cancers (Basel)"},{"issue":"4","key":"31042_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/cdd.2015.36","volume":"23","author":"LM Julian","year":"2015","unstructured":"Julian, L. M. et al. Tissue-specific targeting of cell fate regulatory genes by E2f factors. Cell Death Differ. 23(4), 565\u2013575 (2015).","journal-title":"Cell Death Differ."},{"issue":"17","key":"31042_CR33","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1128\/MCB.00737-14","volume":"34","author":"DP Hollern","year":"2014","unstructured":"Hollern, D. P. et al. The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol. Cell. Biol. 34(17), 3229\u20133243 (2014).","journal-title":"Mol. Cell. Biol."},{"issue":"11","key":"31042_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242179","volume":"15","author":"Y Zhao","year":"2020","unstructured":"Zhao, Y. et al. MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7. PLoS ONE 15(11), e0242179 (2020).","journal-title":"PLoS ONE"},{"issue":"11","key":"31042_CR35","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/mc.23454","volume":"61","author":"F Hao","year":"2022","unstructured":"Hao, F. et al. E2F7 enhances hepatocellular carcinoma growth by preserving the SP1\/SOX4\/Anillin axis via repressing miRNA-383-5p transcription. Mol. Carcinog. 61(11), 975\u2013988 (2022).","journal-title":"Mol. Carcinog."},{"key":"31042_CR36","doi-asserted-by":"crossref","unstructured":"Yang R, et al. E2F7-EZH2 axis regulates PTEN\/AKT\/mTOR signalling and glioblastoma progression. British Journal of Cancer, 2020. 123(9): p. 1445\u20131455. (Erratum in: British Journal of Cancer, 2025. 133(2): p. 272\u2013273.)","DOI":"10.1038\/s41416-020-01032-y"},{"issue":"3","key":"31042_CR37","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s12276-024-01184-4","volume":"56","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. Exp. Mol. Med. 56(3), 600\u2013615 (2024).","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"31042_CR38","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13046-022-02412-3","volume":"41","author":"Z Jing","year":"2022","unstructured":"Jing, Z. et al. NCAPD3 enhances Warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer. J. Exp. Clin. Cancer Res. 41(1), 198 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"31042_CR39","first-page":"1133","volume":"43","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Integrated analysis of the E2F transcription factors across cancer types. Oncol. Rep. 43(4), 1133\u20131146 (2020).","journal-title":"Oncol. Rep."},{"issue":"16","key":"31042_CR40","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2009.25.0977","volume":"28","author":"JS Lee","year":"2010","unstructured":"Lee, J. S. et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J. Clin. Oncol. 28(16), 2660\u20132667 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"31042_CR41","first-page":"2350","volume":"57","author":"RF Souza","year":"1997","unstructured":"Souza, R. F. et al. Frequent mutation of the E2F\u20134 cell cycle gene in primary human gastrointestinal tumors. Cancer Res. 57(12), 2350\u20132353 (1997).","journal-title":"Cancer Res."},{"issue":"10","key":"31042_CR42","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1128\/MCB.20.10.3417-3424.2000","volume":"20","author":"D Wang","year":"2000","unstructured":"Wang, D., Russell, J. L. & Johnson, D. G. E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. Mol. Cell Biol. 20(10), 3417\u20133424 (2000).","journal-title":"Mol. Cell Biol."},{"issue":"9","key":"31042_CR43","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1158\/1541-7786.MCR-15-0120","volume":"13","author":"C Cheng","year":"2015","unstructured":"Cheng, C., Varn, F. S. & Marsit, C. J. E2F4 program is predictive of progression and intravesical immunotherapy efficacy in bladder cancer. Mol. Cancer Res. 13(9), 1316\u20131324 (2015).","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"31042_CR44","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.7150\/ijbs.72534","volume":"18","author":"A Zhang","year":"2022","unstructured":"Zhang, A. et al. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. Int. J. Biol. Sci. 18(7), 3019\u20133033 (2022).","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"31042_CR45","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.18632\/aging.102701","volume":"12","author":"Y Tang","year":"2020","unstructured":"Tang, Y. et al. PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies. Aging (Albany NY) 12(2), 1577 (2020).","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"31042_CR46","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/ijerph13090892","volume":"13","author":"CM Zhang","year":"2016","unstructured":"Zhang, C. M. et al. Role of deficient mismatch repair in the personalized management of colorectal cancer. Int. J. Environ Res. Public Health 13(9), 892 (2016).","journal-title":"Int. J. Environ Res. Public Health"},{"issue":"2","key":"31042_CR47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51(2), 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"issue":"6280","key":"31042_CR48","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280), 1463\u20131469 (2016).","journal-title":"Science"},{"issue":"10","key":"31042_CR49","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"issue":"23","key":"31042_CR50","doi-asserted-by":"publisher","first-page":"9025","DOI":"10.3390\/ijms21239025","volume":"21","author":"JY Mun","year":"2020","unstructured":"Mun, J. Y. et al. E2F1 promotes progression of bladder cancer by modulating RAD54L involved in homologous recombination repair. Int. J. Mol. Sci. 21(23), 9025 (2020).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31042-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31042-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:53:35Z","timestamp":1768474415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31042-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31042"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31042-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in strict compliance with the principles of the Declaration of Helsinki. The research protocol received formal approval from the Institutional Review Board of the Second Hospital of Tianjin Medical University (Approval No. KY2021K003). Written informed consent was obtained from all participating subjects prior to enrollment, and documentation is retained in the hospital\u2019s ethics archives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"1581"}}